← Back to Search

Monoclonal Antibodies

XmAb18087 for Neuroendocrine Carcinoma

Phase 1 & 2
Waitlist Available
Research Sponsored by Xencor, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 (after dosing) up to end of study (up to 163 days)
Awards & highlights

Study Summary

This study is evaluating whether a monoclonal antibody can be used to treat cancer.

Eligible Conditions
  • Neuroendocrine Carcinoma
  • Small Cell Lung Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 (after dosing) up to end of study (up to 163 days)
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 (after dosing) up to end of study (up to 163 days) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Complete and Partial Response Rate as Assessed by RECIST 1.1 Criteria
Number of Participants With Treatment-emergent Adverse Events
Overall Response Rate as Assessed by RECIST 1.1 Criteria
Secondary outcome measures
Duration of Response
Immunogenicity: Number of Participants With Anti-XmAb18087 Antibodies
Overall Survival as Assessed by Per RECIST 1.1 Criteria
+2 more

Side effects data

From 2024 Phase 2 trial • 57 Patients • NCT03004183
21%
Fatigue
13%
Nausea
11%
Back pain
9%
Shortness of Breath
9%
Anemia
9%
Abdominal pain
9%
Diarrhea
7%
Pneumonia
7%
Kidney Injury and/or Infection
7%
Dyspnea
7%
Weight Loss
5%
Malnutrition, Hypercalcemia and Weakness
5%
Pneumothorax
5%
Intractable pain, back pain, hip pain
5%
Activated partial thromboplastin time prolonged
4%
Pleural effusion
4%
Atrial fibrillation with rapid ventricular response
2%
Thrombocytopenia
2%
Respiratory failure
2%
Skin rash
2%
colitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Single Arm

Trial Design

3Treatment groups
Experimental Treatment
Group I: Part C: XmAb18087 monotherapyExperimental Treatment1 Intervention
Part C will enroll participants with previously treated extensive-stage SCLC and consists of safety-run in cohorts followed by an expansion cohort.
Group II: Part B: XmAb18087 + pembrolizumabExperimental Treatment1 Intervention
Part B, will enroll participants with advanced MCC not previously treated with anti-programmed cell death 1 (PD1) or anti-programmed cell death ligand 1 (PDL1) agents, consists of safety run-in cohorts followed by an expansion cohort.
Group III: Part A: XmAb18087 MonotherapyExperimental Treatment1 Intervention
Part A, will enroll participants with previously treated advanced MCC, consists of safety-run in cohorts followed by an expansion cohort.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
XmAb18087
2018
Completed Phase 1
~70

Find a Location

Who is running the clinical trial?

ICON plcIndustry Sponsor
80 Previous Clinical Trials
25,142 Total Patients Enrolled
Xencor, Inc.Lead Sponsor
29 Previous Clinical Trials
2,749 Total Patients Enrolled
Barbara Hickingbottom, MDStudy DirectorVice President, Clinical Development, Xencor
6 Previous Clinical Trials
614 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer
2021. "Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04590781.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top